Hikma Pharmaceuticals USA Inc., et al., Petitioners v. Amarin Pharma, Inc., et al.

The Supreme Court released a decision in a patent fight between Hikma and Amarin over whether a generic drugmaker can still face claims that it actively caused patent infringement after leaving a patented use off its label. The case also asked how courts should treat a complaint at the motion-to-dismiss stage when it does not point to any statement specifically encouraging that patented use.

The answer affects how generic drug companies describe their products and how easily brand-name drug companies can keep these patent cases alive at the start. For example, a company calling its medicine a "generic version" while citing brand-drug sales now has to be judged under the Supreme Court's rule.

Lower courts must now apply the Supreme Court's rule in this case and in similar patent disputes. Drug companies and their lawyers will also review labels and public statements to fit the new standard.

The case asked whether a generic drugmaker can still face induced-infringement claims after excluding a patented use from its label. It also asked when a complaint can survive dismissal without alleging a specific encouraging statement.

Generic drug companies, brand-name drug companies, and trial judges are directly affected. The ruling shapes product descriptions, patent suits, and early dismissal fights.

Lower courts will use the Supreme Court's rule in this case and similar disputes. Drug companies will likely review labels and public statements to reduce future litigation risk.